VVector Bio

VVector Bio

Biotechnology Research

MONTREAL, QC 1,190 followers

Offering excellent CDMO services for viral vector manufacturing to support cell and gene therapy development

About us

VVector Bio is offering expert CDMO services for viral vector manufacturing. The company focuses on the manufacturing of Lentivirus vectors and adeno-associated virus (AAV) from HEK-293 suspension cells along with process and analytical development. VVector Bio also provide services for the manufacturing of AAV from baculovirus-insect cell system. The company also supports projects in the field of vaccines and therapeutics offering excellent services in the manufacturing and process development of recombinant adenovirus vectors, enveloped virus-like particles (eVLPs) and recombinant proteins. Innovation is a big part of the company value toward building a more efficient, reproducible and cost-effective manufacturing process to make cell and gene therapy accessible to every patient in need.

Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
MONTREAL, QC
Type
Privately Held
Founded
2019
Specialties
bioprocessing, biomanufacturing, viral vectors, gene therapy, cell therapy, bioreactors, upstream processing, downstream processing, vaccines, AAV, Adeno-associated virus, Lentivirus , enveloped VLPs, recombinant protein, GMP, manufacturing, CDMO, analytics, and process development

Locations

  • Primary

    141 Avenue du Président-Kennedy

    SB-5585

    MONTREAL, QC H2X 1Y4, CA

    Get directions

Employees at VVector Bio

Updates

  • View organization page for VVector Bio, graphic

    1,190 followers

    Want to learn more about the Critical Quality Attributes of AAV? Check out this great resource!

    View profile for Alina Venereo-Sanchez, graphic

    CEO and Founder at VVector Bio

    If AAV quality keeps you up at night... This paper is a goldmine of insight. The authors provide an overview on nearly every available technique that can be used to measure AAV quality (and all the species you should be measuring). Here is a quick list of the Critical Quality Attributes and methods to be used when analyzing AAV: 𝗣𝗵𝘆𝘀𝗶𝗰𝗮𝗹 𝘁𝗶𝘁𝗲𝗿 (total amount of particles present in the preparation)  - Genome titer by qPCR or ddPCR   - Total capsid by ELISA 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝘂𝘀 𝘁𝗶𝘁𝗿𝗲 (measure of functional yield)  - TCID50  - Gene Transfer Assay 𝗜𝗱𝗲𝗻𝘁𝗶𝘁𝘆 (Ensures high product quality and safety)  - Genetic identity (truncated genome (partials) can translate into  proteins that can be harmful so it is important to sequence these genes (NGS, Sanger sequencing)  - Genome integrity (multiplex dPCR, which employs probe assays with distinct fluorophores targeting various regions of the recombinant AAV genome and Nanopore NGS)  - Methylation status (Measured by bisulfite PCR sequencing: it is not well understood if methylation should be considered as a CQA but there are reports that wild type AAV genome methylation levels are negligible while AAV genome integrated into the host-cell DNA is hypermethylated)   - Capsid identity and stoichiometry (for serotype identification and capsid composition analysis, ELISA, WB, MS-HPLC, Capillary Electroforesis (CE), MS can distinguish between highly homologous AAVs and even detect point mutations) 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 (𝗘𝗺𝗽𝘁𝘆, 𝗳𝘂𝗹𝗹, 𝗽𝗮𝗿𝘁𝗶𝗮𝗹 𝗮𝗻𝗱 𝗼𝘃𝗲𝗿𝗳𝗶𝗹𝗹𝗲𝗱 𝗰𝗮𝗽𝘀𝗶𝗱𝘀) - ELISA + qPCR/dPCR - Analytical ultracentrifugation (AUC)  - Transmission Electron Microscopy (TEM) - Charge Detection Mass Spectrometry (CDMS)  - Size-exclusion chromatography-multiangle light scattering (SEC-MALS)  - Dynamic Light Scattering (DLS)  - Anion Exchange (AEX) HPLC  - Mass photometry 𝗜𝗺𝗽𝘂𝗿𝗶𝘁𝘆 + 𝗦𝗮𝗳𝗲𝘁𝘆 𝗧𝗲𝘀𝘁𝘀 - Residual plasmid DNA - Residual benzonase - Residual Host cell DNA - Residual Host cell proteins - Mycoplasma - Etc. Many thanks to the authors, this is a valuable resource! Theodoros Kontogiannis Is there anything else that you would add? Share it in the comments. #aav #genetherapy #analytics

  • View organization page for VVector Bio, graphic

    1,190 followers

    Valuable insights to consider when choosing a CDMO!

    View profile for Alina Venereo-Sanchez, graphic

    CEO and Founder at VVector Bio

    7 reasons why a big CDMO isn't always the right fit: 𝟭. 𝗖𝗼𝘀𝘁 The larger the organization... The larger the company overhead.  Investors looking for ever-higher ROI.  Someone will have to pay up.  Make sure it isn't you. 𝟮. 𝗣𝗿𝗶𝗼𝗿𝗶𝘁𝘆 Big companies have a lot of projects.  Your precious candidate is just one of many.  Their timelines will be more important than yours.  When you're just one amongst hundreds... You'll just have to sit and wait. 𝟯. 𝗧𝗲𝗰𝗵𝗻𝗶𝗰𝗮𝗹 𝗙𝗮𝗺𝗶𝗹𝗶𝗮𝗿𝗶𝘁𝘆 Sure, that manager you meet at first knows his stuff. But they aren't always the ones doing the work.  Instead, you will work with a technical team.  A team you never met during interviews.  Poor communication is very likely. 𝟰. 𝗖𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 You step into the facility. Boom.  Massive bioreactors glisten under the lights.  They can easily become a major deciding factor.  But at the early stages of development you're in? A bunch of big bioreactors shouldn't drive selection.  Focus on team expertise & GMP tech transfer instead. 𝟱. 𝗙𝗹𝗲𝘅𝗶𝗯𝗶𝗹𝗶𝘁𝘆 Let's be honest.  PD is full of uncertainty.  Best-laid plans can run late.  With the big guys, you get your reserved slot.  End up missing it?  Tough, 100 projects are in line behind you. 𝟲. 𝗦𝗽𝗲𝗲𝗱 The larger they get... The slower they move.  Big CDMOs breed bureaucracy.  More people involved in every decision.  When you need to move fast? A recipe for frustration. 𝟳. 𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 Once you're in, you're little more than a number.  An account that needs services for money.  You'll only get a sliver of their attention.  Fast responses to calls? Unlikely. So what should you do instead? Look for a smaller CDMO that matches your size and growth aspirations:  - Personalized approach with each customer - Short, flexible timelines with reliable yield - A strong track record of quality - Competitive costs - Collaborative So remember... You don't have to go with the big guys. Pick someone you can grow with.  Who cares as much as you do. #cdmo #genetherapy #AAV

    • No alternative text description for this image
  • VVector Bio reposted this

    View profile for Alina Venereo-Sanchez, graphic

    CEO and Founder at VVector Bio

    Empty AAV capsids are a big problem. Therapy efficacy and safety is hindered by them. But this study outlines a method to help fix this issue. Empty capsids are an unfortunate byproduct of AAV production.  They can: - Reduce transduction efficacy - Cause particle aggregation - Trigger adverse immune responses in patients The authors outline a combination of three methods to remove these capsids in downstream: 𝟭. 𝗔𝗻𝗶𝗼𝗻 𝗘𝘅𝗰𝗵𝗮𝗻𝗴𝗲 𝗖𝗵𝗿𝗼𝗺𝗮𝘁𝗼𝗴𝗿𝗮𝗽𝗵𝘆 (𝗔𝗘𝗫):  - Developed to separate full from empty capsids, utilizing dual salt gradients for optimal resolution 𝟮. 𝗗𝘂𝗮𝗹 𝗦𝗮𝗹𝘁 𝗟𝗶𝗻𝗲𝗮𝗿 𝗚𝗿𝗮𝗱𝗶𝗲𝗻𝘁:  - The combination of MgSO₄ and MgCl₂ was employed to achieve superior capsid separation compared to single salt gradients 3. 𝗛𝗼𝗹𝗱𝗶𝗻𝗴 𝗦𝘁𝗲𝗽 𝗣𝗼𝘀𝘁-𝗘𝗺𝗽𝘁𝘆 𝗣𝗲𝗮𝗸:  - Implemented to optimize the resolution between full and empty capsid peaks Main Findings: - The optimized method achieved up to a 5-fold enrichment of full capsids, with final product purity reaching 77% full capsids - The dual salt gradient (MgSO₄ mixed with MgCl₂) provided better separation of full and empty capsids than single salt methods - Adding a low concentration of MgSO₄ to the load buffer reduced what is believed to be AAV degradation on the chromatography column Many thanks to the authors who put this together! Ashton Lavoie, Michael Guerrero and colleagues What are your thoughts on this method? Share them below!

  • View organization page for VVector Bio, graphic

    1,190 followers

    🌍 Revolutionizing Viral Vector Manufacturing Through Global Collaboration! 🌍 (Français ci-dessous) At VVector Bio, we're thrilled to announce our participation in a pioneering project aimed at transforming the landscape of viral vector manufacturing. Backed by a £1.1 million grant from Innovate UK and the National Research Council of Canada, we are joining forces with National Research Council Canada / Conseil national de recherches Canada, Revvity and Abselion to address the critical challenges in cell and gene therapy production. Current viral vector production faces significant hurdles, including low yields, scalability issues, and high costs. Together, we’re tackling these challenges head-on by integrating genomics, epigenomics, and innovative process monitoring to optimize and enhance the HEK-293 cell platform. This collaboration not only underscores our commitment to advancing biomanufacturing but also highlights the importance of international partnerships in driving innovation. We're excited to see the breakthroughs this project will bring, ensuring that life-changing therapies reach patients faster and more efficiently. Read the full press release here: https://lnkd.in/eDk_XE4n #ViralVectors #GeneTherapy #Biomanufacturing #Innovation #VVectorBio #NRC #Revvity #Abselion --- 🌍 Révolutionner la Fabrication de Vecteurs Viraux Grâce à une Collaboration Internationale ! 🌍 Chez VVector Bio, nous sommes ravis d’annoncer notre participation à un projet novateur visant à transformer la fabrication de vecteurs viraux. Soutenus par une subvention de £1,1 million d'Innovate UK et du Conseil national de recherches du Canada, nous unissons nos forces avec le National Research Council Canada / Conseil national de recherches Canada, Revvity, et Abselion pour relever les défis cruciaux de la production de thérapies cellulaires et géniques. La production actuelle de vecteurs viraux est confrontée à des obstacles importants, notamment des rendements faibles, des problèmes d'évolutivité et des coûts élevés. Ensemble, nous relevons ces défis en intégrant des innovations de pointe en génomique, épigénomique et surveillance des processus pour optimiser et améliorer la plateforme cellulaire HEK-293. Cette collaboration souligne non seulement notre engagement à faire progresser les thérapies cellulaires et géniques, mais aussi l'importance des partenariats internationaux pour stimuler l'innovation. Nous sommes impatients de voir les percées que ce projet apportera, garantissant que des thérapies révolutionnaires parviennent plus rapidement et plus efficacement aux patients. Lisez le communiqué de presse complet ici : https://lnkd.in/eDk_XE4n #VecteursViraux #ThérapieGénique #Bioproduction #Innovation #VVectorBio #CNRC #Revvity #Abselion

    • No alternative text description for this image
  • View organization page for VVector Bio, graphic

    1,190 followers

    We are participating in the "ADVANCING MANUFACTURE OF CELL AND GENE THERAPIES VIII" conference in San Diego from Feb 4-8th. Our CEO Alina Venereo-Sanchez is chairing one of the sessions and also presenting our most recent development- A single plasmid technology for AAV production in HEK-293 cells. This technology not only reduce manufacturing cost by reducing the amount of plasmids for transfection but also double AAV yields. Don't hesitate to come talk to us if you are at the conference! #atmps #cellandgenetherapies #manufacturing #cgt

    • No alternative text description for this image

Similar pages

Browse jobs

Funding

VVector Bio 1 total round

Last Round

Seed

US$ 250.0K

See more info on crunchbase